{"id":46918,"date":"2022-08-04T08:01:37","date_gmt":"2022-08-04T06:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/"},"modified":"2022-08-04T08:01:37","modified_gmt":"2022-08-04T06:01:37","slug":"puretech-health-notice-of-half-yearly-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/","title":{"rendered":"PureTech Health: Notice of Half-Yearly Results"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–PureTech Health plc<\/a> (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022.\n<\/p>\n

<\/a><\/p>\n

\nA presentation and conference call for analysts and shareholders will take place at 9:00am EDT \/ 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company’s website at https:\/\/investors.puretechhealth.com\/events-presentations<\/a>.\n<\/p>\n

\nAbout PureTech Health
\n
<\/b>PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech’s most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.\n<\/p>\n

\nFor more information, visit www.puretechhealth.com<\/a> or connect with us on Twitter @puretechh.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements
\n
<\/b>This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the company’s future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPureTech<\/b>
Public Relations
\n
publicrelations@puretechhealth.com<\/a>
Investor Relations
\n
IR@puretechhealth.com<\/a>\n<\/p>\n

\nEU Media<\/b>
Ben Atwell, Rob Winder
\n
+44 (0) 20 3727 1000
\n
ben.atwell@FTIconsulting.com<\/a>\n<\/p>\n

\nU.S. Media<\/b>
Nichole Sarkis
\n
+1 774 278 8273
\n
nichole@tenbridgecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT \/ 2:00pm BST on the day of publication, and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46918","6":"format-standard","7":"category-industry"},"yoast_head":"\nPureTech Health: Notice of Half-Yearly Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PureTech Health: Notice of Half-Yearly Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT \/ 2:00pm BST on the day of publication, and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-04T06:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PureTech Health: Notice of Half-Yearly Results\",\"datePublished\":\"2022-08-04T06:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/\"},\"wordCount\":492,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803006025\\\/en\\\/1396139\\\/21\\\/2022_Horizontal_transparent_white.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/\",\"name\":\"PureTech Health: Notice of Half-Yearly Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803006025\\\/en\\\/1396139\\\/21\\\/2022_Horizontal_transparent_white.jpg\",\"datePublished\":\"2022-08-04T06:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803006025\\\/en\\\/1396139\\\/21\\\/2022_Horizontal_transparent_white.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803006025\\\/en\\\/1396139\\\/21\\\/2022_Horizontal_transparent_white.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/puretech-health-notice-of-half-yearly-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PureTech Health: Notice of Half-Yearly Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PureTech Health: Notice of Half-Yearly Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/","og_locale":"en_US","og_type":"article","og_title":"PureTech Health: Notice of Half-Yearly Results - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT \/ 2:00pm BST on the day of publication, and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-04T06:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PureTech Health: Notice of Half-Yearly Results","datePublished":"2022-08-04T06:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/"},"wordCount":492,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/","url":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/","name":"PureTech Health: Notice of Half-Yearly Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg","datePublished":"2022-08-04T06:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220803006025\/en\/1396139\/21\/2022_Horizontal_transparent_white.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/puretech-health-notice-of-half-yearly-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PureTech Health: Notice of Half-Yearly Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46918"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46918\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}